Abstract: The present disclosure relates to the technical field of antibody drugs, and in particular, to an anti-CD47 antibody or an antigen-binding fragment thereof, a pharmaceutical composition comprising the anti-CD47 antibody or the antigen-binding fragment thereof, and applications thereof. The anti-CD47 antibody or the antigen-binding fragment thereof has significant antitumor activity and high affinity with human CD47 protein, can eliminate the capability of SIRPa to bind to CD47 on a surface of a cell, and does not have significant hemoagglutination activity and thus can be applied to the preparation of an anti-tumor drug.

Abstract: Provided are an anti-Claudin18.2 antibody or an antigen binding fragment thereof, a pharmaceutical composition comprising an anti-Claudin18.2 antibody or an antigen binding fragment thereof, and uses thereof. The antibody and Claudin18.2 have significant binding activity and affinity, have efficient in-vitro ADCC cytotoxic activity against a tumor cell, and can be applied in the preparation of an antineoplastic drug.